Conférences  >  Médecine & Soins de Santé  >  Pharmacologie et développement des médicaments

European Society for Medical Oncology

ESMO TAT, the multi-stakeholder forum gathering key actors in cancer drug development, arrives in one of the most dynamic and best-connected hubs in Asia, making the latest advances in early clinical trials accessible to everyone in the region. Through in-depth discussions on critical topics such as innovation, digital transformation, research methodology, business insights, regulation, and public policy, ESMO TAT Asia aims to drive progress in cancer treatment and research. Located in the lively city of Hong Kong, ESMO TAT Asia promises to be a vibrant gathering with region’s industry, academia, clinicians, and regulators to promote international cooperation and accelerate the anticancer research. Come and join us to chart new paths in cancer drug development in Asia.

ESMO Asia TAT 2025 Secretariat;     Email.: asiacongress@esmo.org

targeted therapies, early drug development, cancer therapeutics, immunotherapy, cytotoxic therapy, cell therapy, biotech, pharmaceutical industry

FDAMap

Each year FDA receives about 3000 applications for new devices via the 510k process, and about 60% of them are rejected either for poor quality application that cannot even be reviewed or for other technical reasons. Submissions to the FDA that are poorly organized, do not follow current practices, contain inconsistencies between documents, have missing or incomplete content, or poor structure will result in significant delays in the clearance process. With multiple review cycles, up to 90 days each, rejections by FDA could stretch the 510k clearance time-lines to 8 months or more. Most of the refuse-to-accept deficiencies are due to the inexperience of the 510k writers, who ignore the FDA rules. Writing and assembling a complete and well structured 510(k) submission will certainly improve the likelihood of FDA clearance on the first round.

FDA, 510(k) Submissions, FDA Regulations, FDA Compliance

Législation en médecine et pharmacologie,    Médecine translationnelle, essais cliniques

CHI

Join a global community of thought leaders and innovators shaping the future of bioprocessing. Dive into cutting-edge research, share insights with industry experts, and tackle the challenges of bioprocess R&D, scale-up, quality, and analytics.

Tél.: [781.972.5400];     Email.: chi@healthtech.com

CHI

In its 23rd year Discovery on Target is the premier event highlighting “hot” drug targets and emerging modalities, technologies and strategies for pursuing those targets. The numerous conferences, symposia, courses and training seminars offer key insights for the successful discovery and development of novel therapeutics, from small molecules to biologics to chimeras and conjugates. The 4 day event covers innovations in target identification and lead generation, which includes cancer therapies, protein degradation, induced proximity, AI/machine learning, membrane proteins, translational models, synthetic biology and other relevant topics. New this year is an increased coverage of GLP-1, MASH and obesity, ADCs and bispecifics and on small molecules targeting DNA.

Tél.: [781.972.5400];     Email.: chi@healthtech.com

Cancérologie,    Biotechnologie

World High Technology Society

The Annual Congress of International Drug Discovery Science & Technology (IDDST), initiated from 2003, has been successfully organized in Shanghai (China), Beijing (China), Shenzhen (China), Nanjing (China), Haikou (China), Suzhou (China), Xi’an (China), Gyeonggi (South Korea), Osaka (Japan), Boston (USA), Kyoto (Japan), Tokyo (Japan), Amsterdam (the Netherlands), Osaka (Japan) and Budapest (Hungary) and has attracted more than 10000 participants from over 50 countries and regions in the previous 20 years. The 21th IDDST (Europe) will be held during June 18-20, 2025 at Stockholm, Sweden. It continues to expand with magnificent scientific and social programs to maximize your network in a free communication meeting environment.

The 21th IDDST (Europe) will host leading scientists from the academia and industry worldwide, to discuss the latest developments in drug discovery and therapy. The program of the coming conference promises to be very interesting for both basic scientists and executives who are working in the field of drug discovery and other related areas, they will offer complete updates of recent developments and present the latest results in the remarkable separate tracks. With the participation of outstanding international experts, we hope productive discussions would stimulate new creative ideas to translate new discoveries into better practice and application.

Uventia

Join us for the 2nd Cleaning Validation Summit, a premier two-day event dedicated to best practices, regulatory expectations and emerging trends in pharmaceutical cleaning validation. This summit will bring together industry experts, regulatory professionals and practitioners to discuss critical topics, from regulatory guidelines (FDA, EMA, PIC/S) to risk-based cleaning validation strategies.

Tél.: [+420 732 640 977];     Email.: info@uventia.com

Cleaning Validation, Containment, Bioprocessing, Aseptic Processing, Regulatory Affairs, Analytical Development, Quality Control, QC, Quality Assurance, QA, Risk Management, Drug, Sterility Assurance

Législation en médecine et pharmacologie,    Biochimie et chimie médicale, toxicologie

Magnus Group

Prepare to immerse yourself in the 5th Edition of the International Vaccines Congress (IVC 2025), taking place from October 23-25, 2025, in the vibrant city of Orlando, Florida, USA! This highly anticipated International Vaccines Congress 2025 will offer a unique hybrid format, seamlessly blending onsite and online experiences to maximize global reach and participation. Dive deep into the latest advancements and transformative trends in vaccine science under the theme: From Discovery to Distribution: The Path of Vaccines.

Tél.: [17029882320];     Email.: vaccines@magnusconference.com

American Society for Experimental Neurotherapeutics (ASENT)

ASENT's 2026 Annual Meeting is the premier neuroscience and neurotherapeutics conference where leaders from providers and prescribers, employers, investors, fast-growing startups, big pharma, policymakers, funders & innovation centers gather to improve the process of bringing neurotherapeutics to market.

Tél.: [8332731556];     Email.: jessica@asent.org

Neurology, Neurotherapeutics, Neuroscience, Biotech, Bioengineering, FDA, NIH, Drug Development, Pipeline Presentations

ELETS Technomedia

The expo will be taking place at Hitex Exhibition Centre from 23rd- 25th April (Thu-Sat) 2026, With the concurrent events Next Gen Pharma Summit and Healthcare Innovation Expo & Summit 2026.It will unite pharmaceutical companies, Drug manufacture, healthcare providers, policymakers, researchers, and technology leaders from around the world on one powerful platform to share knowledge, explore solutions, and foster strategic partnerships.

Tél.: [09560050693];     Email.: indiapharmaexpo1@gmail.com

Pharamaceuticals, Healthcare Technologies, Vaccines, Nanotechnology, Smart Molecule

Salons, foire-exposition,    Génie biomédical

The expo will be taking place t Hitex Exhibition Centre from 23rd- 25th April (Thu-Sat). 2026, with the concurrent events NextGenPharma Summit and Healthcare Innovation Expo & Summit 2026.It will unite pharmaceutical companies,Drug manufacture, healthcare providers, policymakers, researchers, and technology leaders from around the world on one powerful platform to share knowledge, explore solutions, and foster strategic partnerships.

Project Head;     Tél.: [95600 50693];     Email.: milan.jena@elets.in

healthcare, science, pharmaceuticals, biotenchnology, nenotechnology, health